MedPath

Lopinavir/Ritonavir

Generic Name
Lopinavir/Ritonavir
Clinical Trials
Related News

the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

First Posted Date
2020-08-20
Last Posted Date
2020-08-20
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
100
Registration Number
NCT04521400

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Phase 2
Withdrawn
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Drug: Placebo Administration
Other: Questionnaire Administration
First Posted Date
2020-07-02
Last Posted Date
2021-04-26
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT04455958

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

Completed
Conditions
Coronavirus
COVID
Pneumonia
Interventions
Drug: Darunavir/Cobicistat
First Posted Date
2020-06-11
Last Posted Date
2022-08-16
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
400
Registration Number
NCT04425382
Locations
🇶🇦

Hamad Medical Corporation, Doha, Qatar

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Not Applicable
Suspended
Conditions
Pneumonia, Viral
Cytokine Storm
Interventions
Radiation: Ultra-Low-dose radiotherapy
Device: ventilatory support with oxygen therapy
Drug: Piperacillin/tazobactam
Drug: Low molecular weight heparin
Drug: Corticosteroid injection
First Posted Date
2020-05-19
Last Posted Date
2022-03-29
Lead Sponsor
Fundacion GenesisCare
Target Recruit Count
15
Registration Number
NCT04394182
Locations
🇪🇸

Hospital La Milagrosa, GenesisCare, Madrid, Spain

🇪🇸

Hospital Vithas Valencia Consuelo, Valencia, Spain

Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland

Phase 3
Completed
Conditions
Prevention of COVID-19
Interventions
First Posted Date
2020-04-27
Last Posted Date
2021-04-12
Lead Sponsor
Calmy Alexandra
Target Recruit Count
326
Registration Number
NCT04364022
Locations
🇨🇭

Hôpitaux Universitaires de Genève, Geneva, Switzerland

🇨🇭

Ospedale Regionale di Lugano, Lugano, Switzerland

🇨🇭

Universitätsspital Basel and SwissTPH, Basel, Switzerland

and more 1 locations

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

First Posted Date
2020-04-17
Last Posted Date
2021-03-02
Lead Sponsor
Medical University of Vienna
Target Recruit Count
500
Registration Number
NCT04351724
Locations
🇦🇹

Medical University of Innsbruck, Innsbruck, Tirol, Austria

🇦🇹

Wilhelminenspital, Vienna, Austria

🇦🇹

SMZ Ost Donauspital, Vienna, Austria

and more 6 locations

COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir

Phase 3
Conditions
Coronavirus Infections
Post-exposure Prophylaxis
Interventions
First Posted Date
2020-03-25
Last Posted Date
2021-12-14
Lead Sponsor
Unity Health Toronto
Target Recruit Count
123
Registration Number
NCT04321174
Locations
🇨🇦

Sunnybrook Hospital, Toronto, Ontario, Canada

🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇨🇦

St. Paul's Hospital, Vancouver, British Columbia, Canada

and more 1 locations

Trial of Treatments for COVID-19 in Hospitalized Adults

Phase 3
Completed
Conditions
Corona Virus Infection
Interventions
Other: Standard of care
Other: Placebo
First Posted Date
2020-03-20
Last Posted Date
2023-11-29
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Target Recruit Count
1552
Registration Number
NCT04315948
Locations
🇫🇷

Centre Hospitalier Universitaire de Martinique, Fort De France, France

🇫🇷

Centre Hospitalier Andrée Rosemon, Cayenne, France

🇫🇷

CHU APHP Ambroise-Paré, Boulogne-Billancourt, France

and more 57 locations

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Phase 2
Terminated
Conditions
COVID-19
Interventions
First Posted Date
2020-03-13
Last Posted Date
2020-05-27
Lead Sponsor
Asan Medical Center
Target Recruit Count
65
Registration Number
NCT04307693
Locations
🇰🇷

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Phase 2
Completed
Conditions
Novel Coronavirus Infection
Interventions
First Posted Date
2020-02-19
Last Posted Date
2020-04-15
Lead Sponsor
The University of Hong Kong
Target Recruit Count
127
Registration Number
NCT04276688
Locations
🇭🇰

University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy